Skip to content

Clinical and Microbiologic Predictors of Progression to Infection Among Children With Enteric Colonization by Carbapenemase-producing Enterobacterales.

Sep 2026 · The Pediatric Infectious Disease Journal · 0 citations · 31 references
Medicine

Abstract

Background

Carbapenemase-producing Enterobacterales (CPE) colonization is rising globally, yet data on pediatric patients and the risk of progression to infection remain scarce. This study identified clinical/microbiologic profiles and risk factors for progression to infection in colonized children.

Methods

This retrospective cohort study included children colonized by CPE at a tertiary pediatric hospital in Brazil (August 2019-December 2024). Colonization was defined as a CPE-positive rectal swab without clinical signs of infection, while infection was defined as illness caused by the bacteria. Demographic, clinical and microbiologic data were evaluated over a 12-month postcolonization follow-up. Cox proportional hazard models assessed the association between risk factors and the time to CPE infection.

Results

We included 521 CPE colonization episodes in 466 patients (82% with comorbidities; median age 8.8 months [interquartile range: 2.6-64.6]). Klebsiella pneumoniae predominated. Isolates produced Klebsiella pneumoniae carbapenemase (KPC) (56.9%), New Delhi metallo-β-lactamase (31.3%) or both (11.6%). Progression to infection by the same carbapenemase type occurred in 55 patients (11.8%). Independent risk factors were age 6 months or under (hazard ratio [HR]: 2.19, 95% confidence interval [CI]: 1.27-3.79), KPC colonization (HR: 2.00, 95% CI: 1.05-3.81), preexisting liver disease (HR: 2.67, 95% CI: 1.03-6.92) and respiratory disease (HR: 1.95, 95% CI: 1.07-3.57) and the presence of invasive devices (HR: 2.15, 95% CI: 1.16-3.98). Infection-related mortality was 10.9%.

Conclusions

CPE colonization is an emerging threat in vulnerable pediatric populations. Progression to infection is primarily driven by KPC production, chronic comorbidities and invasive devices.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.